XML 28 R77.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative and Other Relationships Collaborative and Other Relationships - Collaboration Agreement (Details) (USD $) | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 1 Months Ended |  | 3 Months Ended | 1 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Mar. 31, 2014 Eisai | Mar. 31, 2014 Sangamo BioSciences | Jan. 31, 2014 Isis Pharmaceuticals | Jan. 31, 2012 Isis Pharmaceuticals | Mar. 31, 2014 Research and development Eisai | Jun. 30, 2014 JAPAN Eisai | Oct. 31, 2014 Subsequent event Isis Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total upfront and milestone payments |  |  |  |  | $ 100,000,000 | $ 20,000,000 |  |  |  |  |
Amount recorded to reflect fair value of options granted |  |  |  |  |  |  |  |  | 17,700,000 |  |
Milestone payments made during period |  |  |  |  |  |  |  |  |  | 35,000,000 |
Research and development | 417,174,000 | 410,017,000 | 1,393,331,000 | 1,021,820,000 |  | 20,000,000 | 45,000,000 | 45,000,000 |  | 21,600,000 | 23,000,000
Additional milestone payment |  |  |  |  | $ 1,000,000,000 | $ 300,000,000 |  |  |  |  |

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | biib_AdditionalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability For Fair Value Of Options Granted Under Agreement + References No definition available. + Details
Name: | biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payments Made During Period. + References No definition available. + Details
Name: | biib_MilestonePaymentsMadeDuringPeriod
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total upfront and milestone payments made to collaborative partner. + References No definition available. + Details
Name: | biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration